Pyxis Oncology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PYXS research report →
Range $5 – $8
Price Chart
About the company
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors.
- CEO
- Thomas Civik
- IPO
- 2021
- Employees
- 56
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on PYXS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $216.49M
- P/E
- -1.08
- PEG
- -0.07
- P/S
- 15.28
- P/B
- 2.85
- EV/EBITDA
- -2.22
- Div Yield
- 0.00%
- Gross Margin
- 99.76%
- Op Margin
- -807.83%
- Net Margin
- -785.54%
- ROE
- -252.36%
- ROIC
- -151.85%
Latest fiscal year · YoY change
- Revenue
- $13.86M-14.2%
- Gross Profit
- $11.47M-26.8%
- Op Income
- $-84,420,000
- Net Income
- $-79,621,000-3.0%
- EPS
- $-1.28+3.0%
- OCF Growth
- -10.1%
- FCF Growth
- -9.7%
- 52W High
- $5.55
- 52W Low
- $1.03
- 50D MA
- $2.16
- 200D MA
- $2.16
- Beta
- 1.41
- RSI (14)
- 52
- Avg Volume
- 1.02M
No earnings-call transcripts are available for PYXS yet.
- Free Float
- 52.6%
- Shares Outstanding
- 119.61M
- Float Shares
- 62.86M
of shares held by institutions
83 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Gordonmd Global Investments LP | 15.54M | ▲ 5.52M |
| Bvf Inc/Il | 11.83M | ▲ 11.83M |
| Orbimed Advisors LLC | 8.36M | ▲ 8.36M |
| Pfizer Inc | 7.03M | 0 |
| Rtw Investments, LP | 6.51M | ▲ 6.51M |
| Laurion Capital Management LP | 4.99M | ▲ 89.00K |
| Vanguard Capital Management LLC | 4.00M | ▲ 1.92M |
| Vanguard Group Inc | 2.34M | ▲ 171.81K |
| Longaeva Partners L.P. | 1.98M | ▲ 1.63M |
| Heights Capital Management, Inc | 1.25M | ▲ 1.25M |
| Wells Fargo & Company/Mn | 1.12M | ▲ 1.12M |
| Blackrock, Inc. | 1.04M | ▲ 167.84K |
Held by 46 ETFs
Biggest fund positions in PYXS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | HUMPHREY RACHEL | other | 34,500 |
| Oct 1, 26 | GordonMD Global Investments LP | buy | 7,172,000 |
| Oct 1, 26 | GordonMD Global Investments LP | buy | 5,517,000 |
| Oct 1, 26 | GordonMD Global Investments LP | buy | 7,546,766 |
| Sep 4, 26 | Civik Thomas | other | 2,503,050 |
| Aug 20, 26 | Dupont Jakob | other | 46,000 |
| Aug 12, 26 | Civik Thomas | other | 250,956 |
| Jun 30, 26 | GordonMD Global Investments LP | other | 0 |
| Jun 30, 26 | GordonMD Global Investments LP | other | 0 |
| Jun 30, 26 | Dupont Jakob | other | 35,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PYXS coverage
Recent articles, reports, and earnings notes.
No research on PYXS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PYXS report →Pyxis Oncology, Inc. (PYXS) Discusses Updated MICVO Phase I Monotherapy Data in Head and Neck Cancer Transcript
seekingalpha.com · Nov 19
Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium
globenewswire.com · Nov 18
Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)
globenewswire.com · Nov 5
Pyxis Oncology to Participate in Upcoming Investor Conferences
globenewswire.com · Oct 28
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
globenewswire.com · Oct 27
Pyxis Oncology (NASDAQ:PYXS) & Precigen (NASDAQ:PGEN) Head to Head Analysis
defenseworld.net · Oct 10
Pyxis Oncology: Better Runway Is Bullish For MICVO's Remaining R&D
seekingalpha.com · Oct 4
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
globenewswire.com · Oct 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.